Plasmonic Nanoparticle Assay for Neutralizing Antibody Quantification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current COVID-19 detection methods, such as lateral flow assays and enzyme-linked immunosorbent assays, are inadequate for determining the amount, type, or function of antibodies, and lack portability and rapidness, especially for neutralization assays which require biosafety level 3 lab settings.
Innovation Solution
Development of plasmonic metal nanoparticle-based colorimetric, spectrometric, or electronic assays that use SARS-CoV-2 antigens and antibodies to form complexes, allowing for rapid, portable, and accurate detection and quantification of neutralizing antibodies through changes in nanoparticle clustering and optical readouts.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If lateral flow assays are used for antibody detection, then the test is inexpensive and suitable for point-of-care use, but it only provides simple positive or negative detection without information on antibody amount, type, or function
Solution Approach 1:
The patent combines the simplicity of lateral flow assay format with the quantitative capability of ELISA by incorporating colorimetric detection reagents directly into the lateral flow strip. This merging allows the test to maintain point-of-care simplicity while providing quantitative antibody measurement capabilities.
Solution Approach 2:
The lateral flow assay is designed to detect multiple antibody types (IgG, IgM, IgA) and provide quantitative information simultaneously. The assay uses different colored particles to distinguish antibody types while providing concentration measurements, making it a multi-functional test that replaces multiple separate tests.
2Measurement precision
If ELISA is used for antibody detection, then it can measure the presence, titer, and type of antibody, but it is complex and can only be performed in a laboratory setting
Solution Approach 1:
The patent extracts the complex laboratory equipment requirements from the ELISA procedure and replaces them with simple lateral flow strip components. The quantitative detection capability is maintained through colorimetric reagents and visual or simple instrumental reading, eliminating the need for plate readers and complex wash steps.
Solution Approach 2:
The patent replaces the mechanical and chemical complexity of ELISA (multiple washing steps, enzyme reactions, plate reading) with a simplified lateral flow mechanism using colorimetric particles that provide direct visual or instrumental quantification without complex procedural steps.
3Measurement precision
If neutralization assays are used to evaluate immune response, then it provides crucial information on humoral response, but it requires biosafety level 3 lab settings which are unavailable to many researchers
Solution Approach 1:
The patent creates a surrogate assay that copies the essential measurement capability of neutralization assays without requiring actual virus handling. By using viral antigens coated on particles and measuring antibody binding, the assay provides neutralization-like information through a safer, simplified format that can be performed in standard laboratories.
Solution Approach 2:
The patent uses disposable lateral flow strips with pre-coated viral antigens that replace the need for expensive and complex BSL3 laboratory infrastructure. The single-use strips make neutralization-style testing accessible to any laboratory or even point-of-care settings, dramatically increasing availability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables inexpensive, fast, and accurate detection of COVID-19 antibodies, including neutralizing antibodies, facilitating the evaluation of immune responses and vaccine efficacy, and can be performed outside laboratory settings, promoting widespread serology testing and clinical use.
Implementation Method 1
plasmonic metal nanoparticles (MNPs) for use in assays to detect and/or quantify neutralizing antibodies
Implementation Method 2
plasmonic metal nanoparticle-based colorimetric, spectrometric, or electronic assays
Data Source
AI summary
The present disclosure provides compositions and methods related to COVID-19 detection. In particular, the present disclosure provides plasmonic metal nanoparticles (MNPs) for use in assays to detect and/or quantify neutralizing antibodies to SARS-CoV-2 in a sample. The compositions and methods of the present disclosure provide a portable, inexpensive, rapid, and accurate antibody assay platform that can be used to evaluate protective immune responses in individuals who have recovered from COVID-19 infection, as well as the efficacy, strength, and duration of vaccines that are under development or in clinical trials.